Diabetes Mellitus, Type 2Phase 3REDWOOD403NCT01089790
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
A Phase 3 study testing Dutogliptin and Sitagliptin in people with Diabetes Mellitus, Type 2, run by Forest Laboratories at 149 sites in United States.
Trial summary
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM). Read more about this study
- Who is it for?
- Ages 18 to 86 years
- Conditions the study is for
- Diabetes Mellitus, Type 2
- What is being tested?
- Dutogliptin and Sitagliptin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 141 participants
- Where
- 149 sitesUnited States
- Study dates
- Mar 2010to Aug 2010
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 86 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have successfully completed all required visits of a qualifying Phase 3 core protocol
- Be currently receiving treatment for T2DM as set forth in the qualifying Phase 3 core protocol
Who cannot join
- Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment
Trial locations and contacts
149 sites in 1 country.
149 sites in 1 country
United States149 sites
Forest Investigative Site 039
Akron, Ohio, 44311
Forest Investigative Site 006
Albany, New York, 12206
Forest Investigative Site 137
Albuquerque, New Mexico, 87102
Forest Investigative Site 101
Albuquerque, New Mexico, 87108
Forest Investigative Site 061
Anaheim, California, 92801
Forest Investigative Site 152
Anaheim, California, 92804
Forest Investigative Site 099
Arlington, Texas, 76014
Forest Investigative Site 121
Arlington, Virginia, 22204
Forest Investigative Site 155
Asheboro, North Carolina, 27203
Forest Investigative Site 102
Ashland, Oregon, 97520
Forest Investigative Site 045
Atlanta, Georgia, 30338
Forest Investigative Site 079
Augusta, Georgia, 30909
Forest Investigative Site 035
Baltimore, Maryland, 21204
Forest Investigative Site 130
Bensalem, Pennsylvania, 19020
Forest Investigative Site 147
Berkeley Heights, New Jersey, 07922
Forest Investigative Site 083
Bethany, Oklahoma, 73008
Forest Investigative Site 064
Birmingham, Alabama, 35205
Forest Investigative Site 020
Birmingham, Alabama, 35235
Forest Investigative Site 156
Boca Raton, Florida, 33432
Forest Investigative Site 148
Brandenton, Florida, 34205
Forest Investigative Site 048
Bristol, Tennessee, 37620
Forest Investigative Site 003
Brockton, Massachusetts, 02301
Forest Investigative Site 055
Brockton, Massachusetts, 02301
Forest Investigative Site 163
Cadillac, Michigan, 49601
Forest Investigative Site 059
Chandler, Arizona, 85225
Forest Investigative Site 094
Charlotte, North Carolina, 28204
Forest Investigative Site 051
Charlotte, North Carolina, 28209
Forest Investigative Site 117
Charlotte, North Carolina, 28277
Forest Investigative Site 114
Chattanooga, Tennessee, 37404
Forest Investigative Site 104
Chattanooga, Tennessee, 37421
Forest Investigative Site 041
Chula Vista, California, 91911
Forest Investigative Site 023
Cincinnati, Ohio, 45242
Forest Investigative Site 073
Clearwater, Florida, 33765
Forest Investigative Site 115
Colorado Springs, Colorado, 80910
Forest Investigative Site 043
Columbus, Ohio, 43201
Forest Investigative Site 056
Corpus Christi, Texas, 78404
Forest Investigative Site 034
Covington, Louisiana, 70433
Forest Investigative Site 071
Dallas, Texas, 75230
Forest Investigative Site 017
Dallas, Texas, 75235
Forest Investigative Site 124
Dallas, Texas, 75251
Forest Investigative Site 057
Dayton, Ohio, 45406
Forest Investigative Site 004
Daytona Beach, Florida, 32117
Forest Investigative Site 002
Dearborn, Michigan, 48126
Forest Investigative Site 077
Decatur, Georgia, 30035
Forest Investigative Site 052
DeLand, Florida, 32720
Forest Investigative Site 088
Denver, Colorado, 80239
Forest Investigative Site 162
DeSoto, Texas, 75115
Forest Investigative Site 042
Dunwoody, Georgia, 30338
Forest Investigative Site 135
Durham, North Carolina, 27704
Forest Investigative Site 054
Edina, Minnesota, 55435
Forest Investigative Site 049
Encinitas, California, 92024
Forest Investigative Site 078
Erlanger, Kentucky, 41018
Forest Investigative Site 005
Eugene, Oregon, 97404
Forest Investigative Site 100
Evansville, Indiana, 47710
Forest Investigative Site 097
Evansville, Indiana, 47713
Forest Investigative Site 113
Gilbert, Arizona, 85295
Forest Investigative Site 096
Goodyear, Arizona, 85395
Forest Investigative Site 013
Grand Island, Nebraska, 68803
Forest Investigative Site 022
Greenbrae, California, 94904
Forest Investigative Site 103
Greer, South Carolina, 29651
Forest Investigative Site 047
Harbor City, California, 90710
Forest Investigative Site 037
Harleysville, Pennsylvania, 19438
Forest Investigative Site 144
Hialeah, Florida, 33012
Forest Investigative Site 129
Hollywood, Florida, 33021
Forest Investigative Site 136
Houston, Texas, 77002
Forest Investigative Site 106
Houston, Texas, 77079
Forest Investigative Site 010
Huntington Park, California, 90255
Forest Investigative Site 014
Irving, Texas, 75039
Forest Investigative Site 139
Irving, Texas, 75039
Forest Investigative Site 062
Jacksonville, Florida, 32205
Forest Investigative Site 126
Jenkintown, Pennsylvania, 19046
Forest Investigative Site 053
Kansas City, Kansas, 66160
Forest Investigative Site 032
Kettering, Ohio, 45429
Forest Investigative Site 072
Las Vegas, Nevada, 89101
Forest Investigative Site 065
Las Vegas, Nevada, 89117
Forest Investigative Site 058
Lenoir, North Carolina, 28645
Forest Investigative Site 107
Lexington, Kentucky, 40504
Forest Investigative Site 070
Los Angeles, California, 90057
Forest Investigative Site 024
Madisonville, Kentucky, 42431
Forest Investigative Site 090
Manning, South Carolina, 29102
Forest Investigative Site 141
Marion, Ohio, 43302
Forest Investigative Site 159
Marion, Ohio, 43302
Forest Investigative Site 001
Medford, Oregon, 97504
Forest Investigative Site 009
Meridian, Idaho, 83646
Forest Investigative Site 161
Miami, Florida, 33136
Forest Investigative Site 157
Miami, Florida, 33143
Forest Investigative Site 154
Miami, Florida, 33175
Forest Investigative Site 050
Miami, Florida, 33183
Forest Investigative Site 122
Miami, Florida, 33186
Forest Investigative Site 125
Miami Lakes, Florida, 33014
Forest Investigative Site 027
Milwaukee, Wisconsin, 53209
Forest Investigative Site 038
Morehead City, North Carolina, 28557
Forest Investigative Site 158
Morrisville, Pennsylvania, 19067
Forest Investigative Site 025
Muscle Shoals, Alabama, 35661
Forest Investigative Site 118
New Bedford, Massachusetts, 02740
Forest Investigative Site 160
New Braunfels, Texas, 78130
Forest Investigative Site 081
New Hyde Park, New York, 11042
Forest Investigative Site 069
New Port Richey, Florida, 34652
Forest Investigative Site 016
New York, New York, 10019
Forest Investigative Site 151
New York, New York, 10032
Forest Investigative Site 149
Norman, Oklahoma, 73069
Forest Investigative Site 111
Northridge, California, 91325
Forest Investigative Site 012
Ocala, Florida, 34471
Forest Investigative Site 150
Omaha, Nebraska, 68114
Forest Investigative Site 015
Orlando, Florida, 32806
Forest Investigative Site 131
Ormond Beach, Florida, 32174
Forest Investigative Site 046
Oxon Hill, Maryland, 20745
Forest Investigative Site 033
Pelzer, South Carolina, 29669
Forest Investigative Site 127
Pembroke Pines, Florida, 33028
Forest Investigative Site 080
Peoria, Arizona, 85381
Forest Investigative Site 030
Peoria, Illinois, 61614
Forest Investigative Site 066
Philadelphia, Pennsylvania, 19152
Forest Investigative Site 098
Phoenix, Arizona, 85020
Forest Investigative Site 133
Phoenix, Arizona, 85023
Forest Investigative Site 068
Renton, Washington, 98057
Forest Investigative Site 031
Riverside, California, 92506
Forest Investigative Site 165
Rockville, Maryland, 20852
Forest Investigative Site 091
Roseville, California, 95661
Forest Investigative Site 084
Roswell, Georgia, 30076
Forest Investigative Site 132
Roswell, Georgia, 30076
Forest Investigative Site 140
Sacramento, California, 95816
Forest Investigative Site 067
Sacramento, California, 95821
Forest Investigative Site 029
Saint Clair Shores, Michigan, 48081
Forest Investigative Site 040
Salisbury, North Carolina, 28144
Forest Investigative Site 076
Salt Lake City, Utah, 84107
Forest Investigative Site 146
San Antonio, Texas, 78205
Forest Investigative Site 109
San Antonio, Texas, 78229
Forest Investigative Site 119
San Antonio, Texas, 78258
Forest Investigative Site 145
San Mateo, California, 94401
Forest Investigative Site 112
Santa Ana, California, 92701
Forest Investigative Site 018
Sarasota, Florida, 34239
Forest Investigative Site 044
Scottsdale, Arizona, 85254
Forest Investigative Site 092
Spokane, Washington, 99207
Forest Investigative Site 123
Springfield, Illinois, 62704
Forest Investigative Site 142
St Louis, Missouri, 63110
Forest Investigative Site 143
St Louis, Missouri, 63110
Forest Investigative Site 075
St. Petersburg, Florida, 33716
Forest Investigative Site 138
Tamarac, Florida, 33319
Forest Investigative Site 036
Tipton, Pennsylvania, 16684
Forest Investigative Site 087
Tucson, Arizona, 85741
Forest Investigative Site 128
Tustin, California, 92780
Forest Investigative Site 028
Virginia Beach, Virginia, 23454
Forest Investigative Site 011
Walnut Creek, California, 94598
Forest Investigative Site 007
Waltham, Massachusetts, 02453
Forest Investigative Site 063
West Hills, California, 91307
Forest Investigative Site 026
West Palm Beach, Florida, 33401
Forest Investigative Site 008
Wichita, Kansas, 67203
Forest Investigative Site 082
Winston-Salem, North Carolina, 27103
Forest Investigative Site 153
Zanesville, Ohio, 43701
About this study
Official title: A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
- Conditions
- Diabetes Mellitus, Type 2
- Being tested
- Dutogliptin, Sitagliptin
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DutogliptinDrug
Also called PHX1149
400 mg tablet, once daily
SitagliptinDrug
Also called Januvia
100 mg capsule (each capsule contains two 50-mg tablets), once daily
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: Dutogliptin |
| 2 | Active comparator | Not described Receives: Drug: Sitagliptin |
What is being measured
The primary outcome is the main question the study is designed to answer.
To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG
Measured: 52 weeks
Secondary outcomes (1)
To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.
Measured: 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2010 (estimated)
- Study startMar 2010
- Primary completionAug 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 141 participants (actual)
Sponsor and investigators
- Lead sponsor
- Forest Laboratories
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Phenomix
- Responsible party
- Sponsor
- Investigators
- Kaity Posada, PharmD, Study director, Forest Research Institute, a subsidiary of Forest Laboratories Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01089790
- Sponsor's protocol ID
- DUT-MD-403
- Acronym
- REDWOOD403
- Status last verified
- Sep 2011
- First submitted
- 17 Mar 2010
- Last updated
- 21 Sep 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Multicenter, Double-blind, Active-Controlled, 52 Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
- ClinicalTrials.gov ID
- NCT01089790
- Acronym / sponsor ID
- REDWOOD403 / DUT-MD-403
- Conditions
- Diabetes Mellitus, Type 2
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 141 participants (actual)
- Lead sponsor
- Forest LaboratoriesIndustry (pharma, biotech, devices)
- Collaborators
- Phenomix
- Study start
- Mar 2010
- Primary completion
- Aug 2010 (actual)
- First posted
- 19 Mar 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Dutogliptin |
| 2 | Active comparator | Drug: Sitagliptin |
Who may qualify
- Ages
- 18 to 86 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Have successfully completed all required visits of a qualifying Phase 3 core protocol
- Be currently receiving treatment for T2DM as set forth in the qualifying Phase 3 core protocol
Key exclusion criteria (1 listed)
- Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DutogliptinAlso: PHX1149400 mg tablet, once daily | Drug | 1 |
| SitagliptinAlso: Januvia100 mg capsule (each capsule contains two 50-mg tablets), once daily | Drug | 2 |
Primary outcome
To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG
Time frame: 52 weeks
1 secondary outcome
To demonstrate maintenance or lowering of HbA1c and fasting plasma glucose.
Time frame: 52 weeks
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2011.
Related trials for Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kaity Posada, PharmD study director
Forest Research Institute, a subsidiary of Forest Laboratories Inc.
149 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Dutogliptin and Sitagliptin in people with Diabetes Mellitus, Type 2, run by Forest Laboratories at 149 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 149 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To demonstrate safety and tolerability of dutogliptin as assessed by vital signs, adverse event reporting, routine clinical laboratory assessments, and ECG (time frame: 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2011.